Validating cancer drug targets

John D. Benson; Ying Nan P Chen; Susan A. Cornell-Kennon; Marion Dorsch; Sunkyu Kim; Magdalena Leszczyniecka; William R. Sellers; Christoph Lengauer

doi:10.1038/nature04873

Validating cancer drug targets

John D. Benson, Ying Nan P Chen, Susan A. Cornell-Kennon, Marion Dorsch, Sunkyu Kim, Magdalena Leszczyniecka, William R. Sellers, Christoph Lengauer

Research output: Contribution to journal › Article › peer-review

119 Scopus citations

Abstract

A cancer drug target is only truly validated by demonstrating that a given therapeutic agent is clinically effective and acts through the target against which it was designed. Nevertheless, it is desirable to declare an early-stage drug target as 'validated' before investing in a full-scale drug discovery programme dedicated to it. Although the outcome of validation studies can guide cancer research programmes, strictly defined universal validation criteria have not been established.

Original language	English (US)
Pages (from-to)	451-456
Number of pages	6
Journal	Nature
Volume	441
Issue number	7092
DOIs	https://doi.org/10.1038/nature04873
State	Published - May 25 2006
Externally published	Yes

ASJC Scopus subject areas

General

Access to Document

10.1038/nature04873

Cite this

@article{9e9006ac000a4ec79708b16921dcb6cd,

title = "Validating cancer drug targets",

abstract = "A cancer drug target is only truly validated by demonstrating that a given therapeutic agent is clinically effective and acts through the target against which it was designed. Nevertheless, it is desirable to declare an early-stage drug target as 'validated' before investing in a full-scale drug discovery programme dedicated to it. Although the outcome of validation studies can guide cancer research programmes, strictly defined universal validation criteria have not been established.",

author = "Benson, {John D.} and Chen, {Ying Nan P} and Cornell-Kennon, {Susan A.} and Marion Dorsch and Sunkyu Kim and Magdalena Leszczyniecka and Sellers, {William R.} and Christoph Lengauer",

year = "2006",

month = may,

day = "25",

doi = "10.1038/nature04873",

language = "English (US)",

volume = "441",

pages = "451--456",

journal = "Nature",

issn = "0028-0836",

publisher = "Nature Publishing Group",

number = "7092",

}

TY - JOUR

T1 - Validating cancer drug targets

AU - Benson, John D.

AU - Chen, Ying Nan P

AU - Cornell-Kennon, Susan A.

AU - Dorsch, Marion

AU - Kim, Sunkyu

AU - Leszczyniecka, Magdalena

AU - Sellers, William R.

AU - Lengauer, Christoph

PY - 2006/5/25

Y1 - 2006/5/25

N2 - A cancer drug target is only truly validated by demonstrating that a given therapeutic agent is clinically effective and acts through the target against which it was designed. Nevertheless, it is desirable to declare an early-stage drug target as 'validated' before investing in a full-scale drug discovery programme dedicated to it. Although the outcome of validation studies can guide cancer research programmes, strictly defined universal validation criteria have not been established.

AB - A cancer drug target is only truly validated by demonstrating that a given therapeutic agent is clinically effective and acts through the target against which it was designed. Nevertheless, it is desirable to declare an early-stage drug target as 'validated' before investing in a full-scale drug discovery programme dedicated to it. Although the outcome of validation studies can guide cancer research programmes, strictly defined universal validation criteria have not been established.

UR - http://www.scopus.com/inward/record.url?scp=33745323666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745323666&partnerID=8YFLogxK

U2 - 10.1038/nature04873

DO - 10.1038/nature04873

M3 - Article

C2 - 16724057

AN - SCOPUS:33745323666

SN - 0028-0836

VL - 441

SP - 451

EP - 456

JO - Nature

JF - Nature

IS - 7092

ER -

Validating cancer drug targets

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this